Trial Profile

An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rezpegaldesleukin (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms INSTRUCT-UC
Sponsors Eli Lilly and Company

Most Recent Events

08 Oct 2022 This trial has been completed in Hungary (End Date: 9 Aug 2022) according to European Clinical Trials Database record.
17 Aug 2022 Status changed from recruiting to discontinued.
13 May 2022 The trial has been discontinued in Czech republic, according to European Clinical trial database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com